A citation-based method for searching scientific literature

Yelena Y Janjigian, Francisco Sanchez-Vega, Philip Jonsson, Walid K Chatila, Jaclyn F Hechtman, Geoffrey Y Ku, Jamie C Riches, Yaelle Tuvy, Ritika Kundra, Nancy Bouvier, Efsevia Vakiani, Jianjiong Gao, Zachary J Heins, Benjamin E Gross, David P Kelsen, Liying Zhang, Vivian E Strong, Mark Schattner, Hans Gerdes, Daniel G Coit, Manjit Bains, Zsofia K Stadler, Valerie W Rusch, David R Jones, Daniela Molena, Jinru Shia, Mark E Robson, Marinela Capanu, Sumit Middha, Ahmet Zehir, David M Hyman, Maurizio Scaltriti, Marc Ladanyi, Neal Rosen, David H Ilson, Michael F Berger, Laura Tang, Barry S Taylor, David B Solit, Nikolaus Schultz. Cancer Discov 2018
Times Cited: 169







List of co-cited articles
747 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
55


Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE-059 Trial.
Charles S Fuchs, Toshihiko Doi, Raymond W Jang, Kei Muro, Taroh Satoh, Manuela Machado, Weijing Sun, Shadia I Jalal, Manish A Shah, Jean-Phillipe Metges,[...]. JAMA Oncol 2018
834
33


Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
Hansjochen Wilke, Kei Muro, Eric Van Cutsem, Sang-Cheul Oh, György Bodoky, Yasuhiro Shimada, Shuichi Hironaka, Naotoshi Sugimoto, Oleg Lipatov, Tae-You Kim,[...]. Lancet Oncol 2014
29

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer.
Seung Tae Kim, Razvan Cristescu, Adam J Bass, Kyoung-Mee Kim, Justin I Odegaard, Kyung Kim, Xiao Qiao Liu, Xinwei Sher, Hun Jung, Mijin Lee,[...]. Nat Med 2018
558
29

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
29


Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study.
Peter C Thuss-Patience, Manish A Shah, Atsushi Ohtsu, Eric Van Cutsem, Jaffer A Ajani, Hugo Castro, Wasat Mansoor, Hyun Cheol Chung, Gyorgy Bodoky, Kohei Shitara,[...]. Lancet Oncol 2017
227
26

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer.
Kohei Shitara, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun-Cheol Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee,[...]. N Engl J Med 2020
240
25

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial.
Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-Hee Ryu, Lorenzo Fornaro, Tomasz Olesiński, Christian Caglevic, Hyun C Chung,[...]. Lancet 2018
599
24

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study.
Josep Tabernero, Paulo M Hoff, Lin Shen, Atsushi Ohtsu, Manish A Shah, Karen Cheng, Chunyan Song, Haiyan Wu, Jennifer Eng-Wong, Katherine Kim,[...]. Lancet Oncol 2018
182
22

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.
J Randolph Hecht, Yung-Jue Bang, Shukui K Qin, Hyun C Chung, Jianming M Xu, Joon O Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M Hoff, Alberto Sobrero,[...]. J Clin Oncol 2016
341
22

Lapatinib plus paclitaxel versus paclitaxel alone in the second-line treatment of HER2-amplified advanced gastric cancer in Asian populations: TyTAN--a randomized, phase III study.
Taroh Satoh, Rui-Hua Xu, Hyun Cheol Chung, Guo-Ping Sun, Toshihiko Doi, Jian-Ming Xu, Akihito Tsuji, Yasushi Omuro, Jin Li, Jin-Wan Wang,[...]. J Clin Oncol 2014
390
21

Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Eirini Pectasides, Matthew D Stachler, Sarah Derks, Yang Liu, Steven Maron, Mirazul Islam, Lindsay Alpert, Heewon Kwak, Hedy Kindler, Blase Polite,[...]. Cancer Discov 2018
161
21

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes.
Razvan Cristescu, Jeeyun Lee, Michael Nebozhyn, Kyoung-Mee Kim, Jason C Ting, Swee Seong Wong, Jiangang Liu, Yong Gang Yue, Jian Wang, Kun Yu,[...]. Nat Med 2015
983
21

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
19

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer.
Eric Van Cutsem, Yung-Jue Bang, Feng Feng-Yi, Jian M Xu, Keun-Wook Lee, Shun-Chang Jiao, Jorge León Chong, Roberto I López-Sanchez, Timothy Price, Oleg Gladkov,[...]. Gastric Cancer 2015
242
19

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Charles S Fuchs, Jiri Tomasek, Cho Jae Yong, Filip Dumitru, Rodolfo Passalacqua, Chanchal Goswami, Howard Safran, Lucas Vieira Dos Santos, Giuseppe Aprile, David R Ferry,[...]. Lancet 2014
18

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
Yelena Y Janjigian, Steven B Maron, Walid K Chatila, Brittanie Millang, Shweta S Chavan, Carly Alterman, Joanne F Chou, Michal F Segal, Marc Z Simmons, Parisa Momtaz,[...]. Lancet Oncol 2020
102
18

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial.
Kei Muro, Hyun Cheol Chung, Veena Shankaran, Ravit Geva, Daniel Catenacci, Shilpa Gupta, Joseph Paul Eder, Talia Golan, Dung T Le, Barbara Burtness,[...]. Lancet Oncol 2016
666
17

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
17

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer.
Yelena Y Janjigian, Johanna Bendell, Emiliano Calvo, Joseph W Kim, Paolo A Ascierto, Padmanee Sharma, Patrick A Ott, Katriina Peltola, Dirk Jaeger, Jeffry Evans,[...]. J Clin Oncol 2018
294
16

Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
M Hofmann, O Stoss, D Shi, R Büttner, M van de Vijver, W Kim, A Ochiai, J Rüschoff, T Henkel. Histopathology 2008
805
15

EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2-Amplified Esophagogastric Cancer.
Francisco Sanchez-Vega, Jaclyn F Hechtman, Pau Castel, Geoffrey Y Ku, Yaelle Tuvy, Helen Won, Christopher J Fong, Nancy Bouvier, Gouri J Nanjangud, Joanne Soong,[...]. Cancer Discov 2019
76
19

Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study).
Akitaka Makiyama, Yasutaka Sukawa, Tomomi Kashiwada, Junji Kawada, Ayumu Hosokawa, Yoshiki Horie, Akihito Tsuji, Toshikazu Moriwaki, Hiroaki Tanioka, Katsunori Shinozaki,[...]. J Clin Oncol 2020
50
30

Tumor mutational load predicts survival after immunotherapy across multiple cancer types.
Robert M Samstein, Chung-Han Lee, Alexander N Shoushtari, Matthew D Hellmann, Ronglai Shen, Yelena Y Janjigian, David A Barron, Ahmet Zehir, Emmet J Jordan, Antonio Omuro,[...]. Nat Genet 2019
14

Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial.
Kohei Shitara, Eric Van Cutsem, Yung-Jue Bang, Charles Fuchs, Lucjan Wyrwicz, Keun-Wook Lee, Iveta Kudaba, Marcelo Garrido, Hyun Cheol Chung, Jeeyun Lee,[...]. JAMA Oncol 2020
188
14

Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients.
S T Kim, K C Banks, E Pectasides, S Y Kim, K Kim, R B Lanman, A Talasaz, J An, M G Choi, J H Lee,[...]. Ann Oncol 2018
59
22

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study.
Kohei Shitara, Hiroji Iwata, Shunji Takahashi, Kenji Tamura, Haeseong Park, Shanu Modi, Junji Tsurutani, Shigenori Kadowaki, Kensei Yamaguchi, Satoru Iwasa,[...]. Lancet Oncol 2019
95
13

Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer.
De-Shen Wang, Ze-Xian Liu, Yun-Xin Lu, Hua Bao, Xue Wu, Zhao-Lei Zeng, Zekun Liu, Qi Zhao, Cai-Yun He, Jia-Huan Lu,[...]. Gut 2019
64
20

Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for EGFR-Amplified Gastroesophageal Adenocarcinoma.
Steven B Maron, Lindsay Alpert, Heewon A Kwak, Samantha Lomnicki, Leah Chase, David Xu, Emily O'Day, Rebecca J Nagy, Richard B Lanman, Fabiola Cecchi,[...]. Cancer Discov 2018
72
18

Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Kohei Shitara, Toshihiko Doi, Mikhail Dvorkin, Wasat Mansoor, Hendrik-Tobias Arkenau, Aliaksandr Prokharau, Maria Alsina, Michele Ghidini, Catia Faustino, Vera Gorbunova,[...]. Lancet Oncol 2018
195
13

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.
F Pietrantonio, M Caporale, F Morano, M Scartozzi, A Gloghini, F De Vita, E Giommoni, L Fornaro, G Aprile, D Melisi,[...]. Int J Cancer 2016
53
22

HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology.
Angela N Bartley, Mary Kay Washington, Carol Colasacco, Christina B Ventura, Nofisat Ismaila, Al B Benson, Alfredo Carrato, Margaret L Gulley, Dhanpat Jain, Sanjay Kakar,[...]. J Clin Oncol 2017
158
12

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Tom Waddell, Ian Chau, David Cunningham, David Gonzalez, Alicia Frances Clare Okines, Clare Okines, Andrew Wotherspoon, Claire Saffery, Gary Middleton, Jonathan Wadsley,[...]. Lancet Oncol 2013
502
12


Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
11

Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma.
Jihun Kim, Cameron Fox, Shouyong Peng, Mark Pusung, Eirini Pectasides, Eric Matthee, Yong Sang Hong, In-Gu Do, Jiryeon Jang, Aaron R Thorner,[...]. J Clin Invest 2014
78
14


Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial.
Elizabeth C Smyth, Andrew Wotherspoon, Clare Peckitt, David Gonzalez, Sanna Hulkki-Wilson, Zakaria Eltahir, Matteo Fassan, Massimo Rugge, Nicola Valeri, Alicia Okines,[...]. JAMA Oncol 2017
239
11


Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma.
Steven B Maron, Leah M Chase, Samantha Lomnicki, Sara Kochanny, Kelly L Moore, Smita S Joshi, Stacie Landron, Julie Johnson, Lesli A Kiedrowski, Rebecca J Nagy,[...]. Clin Cancer Res 2019
72
15

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
711
11

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Florian Lordick, Yoon-Koo Kang, Hyun-Cheol Chung, Pamela Salman, Sang Cheul Oh, György Bodoky, Galina Kurteva, Constantin Volovat, Vladimir M Moiseyenko, Vera Gorbunova,[...]. Lancet Oncol 2013
582
11

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
Jin Li, Shukui Qin, Jianming Xu, Jianping Xiong, Changping Wu, Yuxian Bai, Wei Liu, Jiandong Tong, Yunpeng Liu, Ruihua Xu,[...]. J Clin Oncol 2016
536
10

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa,[...]. Clin Cancer Res 2016
278
10

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.
Filippo Pietrantonio, Giovanni Fucà, Federica Morano, Annunziata Gloghini, Simona Corso, Giuseppe Aprile, Federica Perrone, Ferdinando De Vita, Elena Tamborini, Gianluca Tomasello,[...]. Clin Cancer Res 2018
57
17

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
David Cunningham, William H Allum, Sally P Stenning, Jeremy N Thompson, Cornelis J H Van de Velde, Marianne Nicolson, J Howard Scarffe, Fiona J Lofts, Stephen J Falk, Timothy J Iveson,[...]. N Engl J Med 2006
10

Effect of Fluorouracil, Leucovorin, and Oxaliplatin With or Without Onartuzumab in HER2-Negative, MET-Positive Gastroesophageal Adenocarcinoma: The METGastric Randomized Clinical Trial.
Manish A Shah, Yung-Jue Bang, Florian Lordick, Maria Alsina, Meng Chen, Stephen P Hack, Jean Marie Bruey, Dustin Smith, Ian McCaffery, David S Shames,[...]. JAMA Oncol 2017
152
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.